Amgen (AMGN) has attracted the attention of 9 analysts in the recent quarter, leading to a spectrum of opinions ranging from bullish to bearish. Analysts have set 12-month price targets for Amgen, with an average target of $314.11, a high estimate of $342.00, and a low estimate of $261.00. The current average target has seen a positive uptick of 1.36% from the previous average.
When delving into the breakdown of analyst ratings, it becomes apparent that financial experts are closely monitoring Amgen’s performance. Key analysts have been adjusting their ratings and price targets, providing valuable insights into the company’s market positioning and future trajectory. Amgen’s robust portfolio includes a range of successful drugs in various therapeutic areas such as oncology, inflammation, and rare diseases.
From a market capitalization perspective, Amgen stands out with a significant size and market recognition. The company has demonstrated impressive revenue growth, with a notable 9.43% increase as of June 30, 2025, although its growth rate lags behind industry peers in the Health Care sector. Amgen’s strong net margin of 15.6% underscores its solid financial performance, while its return on equity (ROE) and return on assets (ROA) metrics surpass industry benchmarks, reflecting efficient financial management.
Despite its strong financial performance, Amgen’s higher debt-to-equity ratio compared to industry averages indicates a greater reliance on borrowed funds and poses a higher level of financial risk. Analyst ratings play a crucial role in providing investors with insights into stock performance, leveraging the expertise of financial specialists who analyze company fundamentals and industry trends to generate ratings and price targets. It is important to note that while analyst ratings offer valuable guidance, they are ultimately opinions and not guarantees of stock performance.
Staying informed about analyst perspectives on Amgen and other stocks can help investors make strategic investment decisions. By monitoring analyst ratings and updated price targets, investors can gain a better understanding of market sentiment and potential opportunities in the biotechnology sector. Benzinga’s comprehensive rankings and insights provide investors with essential metrics and analyses to navigate the stock market effectively.
Key Takeaways:
– Amgen has garnered attention from 9 analysts, with an average price target of $314.11.
– The company’s diverse drug portfolio includes treatments for oncology, inflammation, and rare diseases.
– Amgen demonstrates strong financial performance, with notable revenue growth and profitability metrics.
– Analyst ratings offer valuable insights into stock performance but should be considered alongside other factors when making investment decisions.
Read more on benzinga.com